Expertise in
12
conditions

Dr. Daniel Furst

Rheumatology
Pacific Arthritis Care Center Inc.
5230 Pacific Concourse Dr Ste 100, 
Los Angeles, CA 
Offers Telehealth
54 Years of Experience
Expertise in
12
conditions
Pacific Arthritis Care Center Inc.
5230 Pacific Concourse Dr Ste 100, 
Los Angeles, CA 

Overview

Daniel Furst is a Rheumatologist in Los Angeles, California. Dr. Furst has been practicing medicine for over 54 years is highly rated in 12 conditions, according to our data. His top areas of expertise are Systemic Sclerosis (SSc), Scleroderma, Rheumatoid Arthritis (RA), and Arthritis.

His clinical research consists of co-authoring 436 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Rheumatology

Licenses

Internal Medicine in CA

Hospital Affiliations

Hoag Memorial Hospital Presbyterian

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Health Net

Accepted plan types not found. Please verify directly with the provider.

HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Health Advantage
  • HMO
  • INSURANCE PLAN
  • MEDICARE DISCOUNT CARD
  • MEDICARE MAPD
View 14 Less Insurance Carriers -

Locations

Pacific Arthritis Care Center Inc.
5230 Pacific Concourse Dr Ste 100, Los Angeles, CA 90045
Other Locations
Daniel Furst MD A Professional Corp.
575 E Hardy St Ste 321, Inglewood, CA 90301

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: March 06, 2025
Intervention Type: Drug
Study Drug: HZN-825
Study Phase: Phase 2
A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis
A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis
Enrollment Status: Completed
Publish Date: January 07, 2025
Intervention Type: Other, Drug, Biological, Procedure
Study Drugs: Anti-thymocyte globulin, Cyclophosphamide, Filgrastim, Mycophenolate mofetil, Plerixafor
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics, and Explore Efficacy of TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics, and Explore Efficacy of TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: June 28, 2024
Intervention Type: Biological, Other
Study Drug: Tepezza Anti-IGF-1 Receptor Monoclonal Antibody
Study Phase: Phase 1
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: August 30, 2023
Intervention Type: Drug
Study Drug: Belumosudil (KD025)
Study Phase: Phase 2
Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)
Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)
Enrollment Status: Completed
Publish Date: November 23, 2021
Intervention Type: Drug, Biological
Study Drug: Zostavax Herpes Zoster Vaccine
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: March 29, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
Pilot Study to Evaluate Subcutaneous Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background- a Pilot, Double-blind, Placebo-controlled, Randomized, Controlled Trial.
Pilot Study to Evaluate Subcutaneous Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background- a Pilot, Double-blind, Placebo-controlled, Randomized, Controlled Trial.
Enrollment Status: Withdrawn
Publish Date: November 16, 2020
Intervention Type: Drug
Study Phase: Not Applicable
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan: A Prospective Single Center, Open Label, Pilot Study
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan: A Prospective Single Center, Open Label, Pilot Study
Enrollment Status: Completed
Publish Date: November 02, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Enrollment Status: Completed
Publish Date: February 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

435 Total Publications

Isolated muscular tuberculosis with secondary haemophagocytic lymphohistiocytosis.
Isolated muscular tuberculosis with secondary haemophagocytic lymphohistiocytosis.
Journal: The Lancet. Rheumatology
Published: September 18, 2025
Similar Doctors
Expertise in
21
conditions
Dr. Tanaz A. Kermani
Rheumatology
Expertise in
21
conditions
Dr. Tanaz A. Kermani
Rheumatology
2020 Santa Monica Boulevard, Suite 540, 
Santa Monica, CA 
 (9.3 miles away)
310-582-6350
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tanaz Kermani is a Rheumatologist in Santa Monica, California. Dr. Kermani is highly rated in 21 conditions, according to our data. Her top areas of expertise are Temporal Arteritis, Giant Cell Arteritis (GCA), Vasculitis, and Takayasu Arteritis. Dr. Kermani is currently accepting new patients.

Expertise in
22
conditions
Dr. Daniel J. Wallace
Rheumatology
Expertise in
22
conditions
Dr. Daniel J. Wallace
Rheumatology
8730 Alden Dr, 
Los Angeles, CA 
 (8.9 miles away)
310-423-3870
Languages Spoken:
English
See accepted insurances

Daniel Wallace is a Rheumatologist in Los Angeles, California. Dr. Wallace is highly rated in 22 conditions, according to our data. His top areas of expertise are Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Sjogren Syndrome, and Rheumatoid Arthritis (RA).

Expertise in
8
conditions
Dr. Christina M. Charles-Schoeman
Rheumatology
Expertise in
8
conditions
Dr. Christina M. Charles-Schoeman
Rheumatology

The Regents Of The University Of California

2020 Santa Monica Blvd, Suite 210, 
Santa Monica, CA 
 (9.3 miles away)
310-458-2381
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Christina Charles-Schoeman, MD is a Rheumatology Specialist in Los Angeles, CA. Dr. Charles-Schoeman has extensive experience in Rheumatologic Muscular Diseases and Osteoporosis & Screening. She is affiliated with Ronald Reagan UCLA Medical Center. Dr. Charles-Schoeman is highly rated in 8 conditions, according to our data. Her top areas of expertise are Dermatomyositis, Polymyositis, Myositis, and Rheumatoid Arthritis (RA).

Frequently Asked Questions about Dr. Daniel Furst

How do I make an appointment with Dr. Daniel Furst?

You can book an appointment with Dr. Daniel Furst by calling their office at 310-297-9221. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel Furst a top-rated expert for Systemic Sclerosis (SSc)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel Furst is classified as an Elite expert for Systemic Sclerosis (SSc), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel Furst specialize in?

While Dr. Daniel Furst is a Rheumatology, they have specific expertise in Systemic Sclerosis (SSc), Scleroderma, and Rheumatoid Arthritis (RA). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Daniel Furst participate in research or clinical trials?

Yes. Dr. Daniel Furst has published 435 articles and abstracts on conditions like Systemic Sclerosis (SSc). You can view a list of Dr. Daniel Furst's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Daniel Furst accept my insurance?

Dr. Daniel Furst accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 310-297-9221 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Furst's expertise for a condition
ConditionClose
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile